Table 2.
Relative expression levels of the genes investigated.
| Gene | Expression level in untreated patients Mea (25%–75%)b |
Expression level in treated patients Me (25%–75%) |
Expression level in neurological control Me (25%–75%) |
|---|---|---|---|
| ALDH1A1 | 1.08 (0.71–1.53) | 1.60 (0.94–2.08) | 0.95 (0.33–1.64) |
| ATP13A2 | 1.94 (1.43–3.03) c | 2.14 (1.29–4.86) | 0.86 (0.46–1.62) |
| LRRK2 | 0.44 (0.31–1.26) | 0.56 (0.41–1.42) | 0.83 (0.37–1.35) |
| PARK7 | 1.68 (0.96–2.51) | 1.60 (1.32–2.20) | 1.00 (0.64–1.50) |
| PINK1 | 0.75 (0.25–1.40) | 1.29 (0.28–3.37) | 0.26 (0.12–0.56) |
| PDHB | 1.46 (0.65–2.16) | 2.10 (0.58–2.36) | 1.32 (1.01–1.55) |
| SNCA | 0.24 (0.06–1.16) | 0.16 (0.04–0.24) | 0.14 (0.02–0.99) |
| ZNF746 | 2.33 (0.96–4.60) | 2.46 (0.66–5.01) | 1.07 (0.33–1.64) |
aMe: median; b25%–75%: 25–75 percentiles. cThe data in bold are statistically significant (p < 0.05).